Table 1.

Cohort characteristics

CharacteristicAll randomized (n = 672)IHC Cohort (n = 492)PAM50 cohort (n = 398)
Age (median and range)45.7 y (26–58)45.6 y (27–58)45.5 y (27–58)
Stage
 I10%10%10%
 II84%85%84%
 III6%5%6%
Nodal status
 025%24%25%
 1—356%56%55%
 ≥ 419%20%20%
Clinical ER/PR status
 ER+ and/or PR+75%74%73%
 ER/PR unknown14%14%15%
 ER/PR11%12%12%
Chemotherapy
 Cyclophosphamide, methotrexate and fluorouracil45%44%43%
 Doxorubicin and cyclophosphamide33%32%32%
 Cyclophosphamide, epirubicin and fluorouracil22%24%25%
Grade
 I19%26%24%
 II30%42%42%
 III22%31%34%
 Missing29%2%0%